Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2248)	12/7/2000 1:35:44 PM
From: tom pope	Read Replies (1) of 52153

Peter, there's an irony in here - if the acquiring company may now leave the difference of price over book on the balance sheet indefinitely, isn't the net effect the ex post facto capitalization of R&D? Edit- in fact it's better than that (or worse, depending on your point of view) - if the company is sold at a significant premium, a great deal more than the expensed R&D might end up on the asset side of the acquiror's balance sheet!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next